Editor’s note: This is a developing news story. Please check back soon for updates.
The FDA granted fast track designation to SAR446597, an intravitreal gene therapy for the treatment of geographic atrophy due to age-related macular degeneration, according to a press release from Sanofi.
The one-time injection is designed to target and inhibit two components of the complement pathway: C1s in the classical pathway and factor Bb in the alternative pathway.
“This dual-targeting approach potentially offers clinical advantages by providing sustained complement suppression within the